Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)

What Was Tested

This randomized controlled trial paper looks at Insulin Glargine and Lixisenatide.

However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Insulin Glargine study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Insulin Glargine group a baseline to be compared against.

The Insulin Glargine group and the comparison group ran side by side rather than switching.

The primary end point was HbA1c change after randomization.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Glargine, Insulin, Long-Acting and Peptides.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Insulin Glargine and Lixisenatide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Diabetes care), a journal based in United States.

More context: the Insulin Glargine compound page and the Lixisenatide compound page.